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Cachexia is “a complex metabolic syndrome associated with underlying illness and 
characterised by muscle loss, with or without loss of fat” (Evans et al. 2008). It is a 
common syndrome associated with chronic illness and has been variably defined.  
One working definition of cachexia incorporates weight loss of at least 5% within ≤12 
months or BMI <20 kg/m2 plus three of the following five features: decreased muscle 
strength; fatigue; anorexia; low fat-free mass index; abnormal biochemistry 
(increased inflammatory markers [CRP, IL-6], anaemia [Hb <120 g/L], low serum 
albumin [<32g/L] (Evans et al., 2008). Currently, there is no standardised treatment 
available for cachectic patients and the presence of the cachectic syndrome, 
associated with any chronic disease trajectory, increases mortality (Von Haeling & 
Anker, 2010). Cachexia is present in a range of chronic illness including: cancer; 
cardiac disease; kidney disease and AIDS. Most work on the key features of 
cachexia has been in cancer (Fearon et al. 2011).  
To date, limited attention has been devoted to cachexia in other chronic disorders 
such as chronic kidney disease (CKD) (Mak et al. 2011). For renal cachexia there 
are no standardised definitions or inclusion criteria to help inform practice or 
research (Reid et al. 2013). The importance of identifying the disease specific key 
features of cachexia is evident in the cancer population, where such work has 
allowed the biopsychosocial impact of this syndrome to be researched and potential 
therapeutic inventions trialled (Reid, 2014).  The impact of cachexia in the renal 
population may parallel that in cancer, but to date research ascertaining this is 
lacking.  
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Can we simply assume that the same diagnostic criteria and prognostic data apply in 
renal populations as in others such as cancer and heart failure? To do so without 
careful research would be inadvisable. Several features associated with CKD, e.g. 
proteinuria and renal anaemia, mean that some diagnostic criteria may reflect renal 
disease per se, rather than the cachectic state. Measures of fatigue, anorexia and 
low muscle mass may be impacted by alterations in biochemistry due to kidney 
failure, but also by treatment for CKD (e.g. dialysis). These uncertainties mean that 
studies to validate the definition and prognosis of cachexia specifically in renal 
populations are essential. Cachexia is known to be a polysymptomatic 
syndrome making an exact diagnosis difficult. Furthermore, symptoms commonly 
associated with cachexia, such as anorexia and fatigue, can be present in individuals 
without cachexia. More research is needed to establish if cachexia is a single well 
defined entity in patients with CKD and if so to define the characteristic symptoms, 
signs and biochemical features of cachexia in the renal population. 
 
The clinical management of cachexia in persons with CKD is challenging (Mak et al. 
2011) partly due to the difficulty discriminating cachexia from other causes of 
malnutrition.  Indeed, the term malnutrition should probably be avoided in cachexia 
as it suggests that the primary problem is failure of nourishment. This implies that 
cachexia can be corrected by overcoming problems with absorption or by use of 
nutritional supplements. For persons with CKD there is now a greater emphasis on 
defining clinical markers for Protein Energy Wasting (PEW) which precedes cachexia 
and specialised diagnostic tools are being developed and tested (Cuppari et al. 
2014). Cachexia is seen as a severe form of PEW (Fouque, 2008; Jadeja & Kher, 
2012), however it is still important to be able to clinically differentiate between 
cachexia and PEW as each state may require distinct management strategies. An 
ability to accurately discriminate between renal cachexia and PEW may also be 
important when defining target groups for future trials of novel pharmacological or 
nutritional interventions.  
 
In an attempt to define cachexia in patients with CKD, a working group was 
established and met at the British Renal Society conference in Glasgow 2014. This 
initial workshop invited key health care professionals from the United Kingdom 
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interested in cachexia and its management in CKD. Discussion focused on Evans’ 
(2008) work and its appropriateness for a renal population. It was agreed that 
defining cachexia in CKD required further exploratory work to enable refinement of 
key defining characteristics. A subsequent workshop was held in Northern Ireland (in 
2014) in order to engage health care professionals, academics and service users in 
an attempt to improve understanding of cachexia in renal disease. The workshop 
included guest lectures from: Professor Denis Fouque (Professor of Nephrology and 
Director of the Clinical Renal Unit , Université de Lyon, France); Dr David Seres 
(Director, Medical Nutrition, Associate Professor of Medicine in the Institute of 
Human Nutrition Department of Medicine, Columbia University USA); and Dr Damian 
Fogarty (Consultant Nephrologist Belfast Trust and previous Chairman, UK Renal 
Registry). Representatives from both the British Kidney Patient Association and 
Northern Ireland Kidney Patient Association also attended this workshop. These 
workshops have reinforced the need to further refine the definition of renal cachexia 
and how it differs from PEW and malnutrition. The urgent need to conduct 
epidemiological work to determine the key defining characteristics of cachexia in 
renal disease was emphasised. 
 
In summary, there remains limited consensus on the defining characteristics of renal 
cachexia partly due to limited epidemiological research on this syndrome in CKD. 
There is a pressing need to robustly define the inclusion and exclusion criteria for 
renal cachexia to help target future research of this syndrome and its optimum 
therapy. 
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